Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06706765 · ClinicalTrials.gov registry record · Early Phase 1
Group Telehealth Behavioral Cough Suppression Therapy
A Early Phase 1 study of Refractory Chronic Cough, sponsored by University of Montana.
- Recruiting
- Registry status
- Early Phase 1
- Development phase
- 60
- Enrollment target
- 1
- Study location
NCT06706765: Recruiting Early Phase 1 study of Refractory Chronic Cough, sponsored by University of Montana.
NCT06706765 is a Early Phase 1 study of Refractory Chronic Cough that is actively recruiting participants, run by University of Montana. The registered enrollment target is 60 participants, below the 379-participant average among 5 other Refractory Chronic Cough trials with a reported enrollment target (84% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06706765, a Early Phase 1 study of Refractory Chronic Cough, is actively recruiting participants, sponsored by University of Montana.
- RECRUITING
- Registry status
- Early Phase 1
- Development phase
- 60 participants
- Enrollment target
- 1
- Study location
Study Summary
The purpose of this study is to investigate the effectiveness of behavioral cough suppression therapy (BCST) in managing refractory chronic cough (RCC) within a group telehealth setting. RCC is a cough that has lasted at least 8 weeks and has not resolved with standard medical treatment. BCST is a research-based treatment provided by specialty-trained speech-language pathologists (SLPs) for patients with RCC. Although the treatment works very well for a large proportion of patients in a standard one-on-one format, there are a limited number of SLPs available to provide this treatment and patients living in rural areas do not typically have access to an SLP trained in BCST. If BCST can effectively be delivered in a group telehealth model, it would significantly improve accessibility to the treatment.
Conditions Studied
Interventions
- BEHAVIORAL Behavioral Treatment
Study Locations (1)
Montana
- University of Montana - Missoula
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 60 participants |
| Start Date | 2024-03-22 |
| Est. Completion | 2025-01-31 |
| Phase | Early Phase 1 |
What NCT06706765 shows while recruiting
NCT06706765 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 60 participants, a relatively small participant target, below the 379-participant average among 5 other Refractory Chronic Cough trials with a reported enrollment target (84% lower).
The record links to 1 condition, with Refractory Chronic Cough appearing as the primary indexed condition, and to 1 intervention - of which Behavioral Treatment is the first listed.
NCT06706765 reports a single indexed study location in Montana.
Frequently Asked Questions
What is clinical trial NCT06706765 about?
NCT06706765 is a clinical study titled "Group Telehealth Behavioral Cough Suppression Therapy". The purpose of this study is to investigate the effectiveness of behavioral cough suppression therapy (BCST) in managing refractory chronic cough (RCC) within a group telehealth setting. RCC is a cough that has lasted at least 8 weeks and has not resolved with standard medical treatment. BCST is a r...
What is the current status of trial NCT06706765?
This trial is currently recruiting. It is a Early Phase 1 study. The enrollment target is 60 participants. The study started on 2024-03-22. Estimated completion is 2025-01-31.
What conditions does trial NCT06706765 study?
This clinical trial studies the following conditions: Refractory Chronic Cough.
What interventions are being tested in trial NCT06706765?
The interventions under investigation include: Behavioral Treatment (BEHAVIORAL).
Who is sponsoring clinical trial NCT06706765?
This trial is sponsored by University of Montana, which has 24 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06706765 being conducted?
This trial has 1 study location across Montana. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Refractory Chronic Cough
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
A 24-Week Study of the Efficacy and Safety of BLU-5937 in Adults With Refractory Chronic Cough
RECRUITING · Phase 3
-
Cough Management Wellness App for Refractory or Unexplained Chronic Cough
RECRUITING · NA
-
Efficacy of Two Doses of Duloxetine and Amitriptyline in Subjects With Refractory Chronic Cough
RECRUITING · Phase 2
-
A 52-Week Study of the Efficacy and Safety of BLU-5937 in Adults With Refractory Chronic Cough
ACTIVE NOT RECRUITING · Phase 3
-
Placebo-controlled, Single and Multiple Dose Study in Healthy Volunteers and Refractory Chronic Cough Patients to Assess the Safety, Tolerability, and Pharmacokinetics of Two Formulations of NTX-1175
COMPLETED · Phase 1
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00576069 · 60 participants
Mechanism(s)of Airflow Limitation in Moderate-severe Persistent Asthma
- NCT01297400 · 60 participants · Phase 2
Phase 2 Pilot Study of the Safety and Efficacy of Topical MW-III in Thermal Burns
- NCT01734122 · 60 participants
Stereotactic Radiosurgery for Essential Tremor and Parkinsonian Tremor
- NCT01804634 · 60 participants · Phase 2
Reduced Intensity Haploidentical BMT for High Risk Solid Tumors
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI